Cancer Drug Development Lab
The Cancer Drug Development Lab is dedicated to accelerating the drug discovery process by developing new technologies and integrated systems biology approaches in order to translate genomic data rapidly to new anti-cancer drug compounds. The purpose of the lab is to develop and discover small molecule, antibody, and nucleic acid based agents to target the most promising gene and gene products for advancement to preclinical and clinical testing. This research is setting the stage for the ability to rapidly and effectively translate genomics into advances in anti-cancer drug development.
Current projects:
1. Identification and validation of Rapamycin response genes.
2. Accelerated discovery and validation of novel tumor suppressor genes in breast cancer.
3. Validation of genes that modulate Doxorubicin therapy.
4. Validation of the role of S100P in growth and survival of hormone refractory prostate cancer.
Staff:
Spyro Mousses, Ph.D., Unit Head
|
E-MAIL THIS ARTICLE
PRINT THIS PAGE
Podcasts
NewsFeed